Distributed on behalf of Conavi Medical.
Two Views, One Catheter: A
Clearer Look Inside Heart Arteries
When doctors treat a blocked heart artery, they need to understand more than where the blockage is. They also need to see the artery’s size, the material building up inside it, and whether treatment has restored enough room for blood to flow. That’s where companies such as Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), Philips (NYSE: PHG), Boston Scientific (NYSE: BSX), Terumo (OTC: TRUMY), and Heartflow Inc. (NASDAQ: HTFL) may be able to help.
For example, Conavi Medical is using two imaging tools, including intravascular ultrasound, or IVUS, and optical coherence tomography, or OCT. One uses sound waves to look deeper into the artery wall. The other uses light to show very small details near the artery’s inner surface.
Think of IVUS as a way to see the artery’s overall structure. It helps doctors assess vessel size and understand how much plaque has built up within the wall. OCT provides a closer look at the inner surface. Its detailed images can help doctors examine plaque features and the position of a stent, the small mesh tube used to help keep an artery open.
However, each tool has limits. Ultrasound can see deeper, but it does not show the same fine detail as OCT. OCT captures smaller features, but its light cannot reach as deeply. Combining them gives doctors two useful views. In addition, both sets of images can also be collected as a single catheter moves back through the artery. The system aligns the views, helping doctors compare the same location without matching separate imaging runs themselves. This may simplify procedures that would otherwise require two devices.
The main benefit is straightforward: more information about the same artery, gathered together, can help doctors make decisions before, during, and after treatment.
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF) Just Completed First U.S. Commercial Placement and Clinical Cases with its OCTIV Hybrid Imaging System to Guide Coronary Interventions
Conavi Medical Corp., a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, just announced the completion of the first U.S. placement and clinical cases with OCTIV™, powered by Novasight™, its FDA-cleared hybrid intravascular imaging system.
“The first placement and clinical cases with OCTIV move our next-generation system from FDA clearance into clinical use in the United States,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “OCTIV brings the complementary information from IVUS and OCT into one catheter, with design enhancements focused on image quality, deliverability and ease of use.
OCTIV combines intravascular ultrasound and optical coherence tomography in a single imaging catheter, providing simultaneous, co-registered views of coronary arteries to support assessment of coronary artery disease and guide percutaneous coronary intervention. The placement and first cases mark a milestone in Conavi’s targeted U.S. commercial rollout following FDA 510(k) clearance.
Hybrid Imaging and Key Differentiating Features
OCTIV brings together the following capabilities to support image-guided coronary interventions:
· Hybrid IVUS–OCT imaging: Simultaneous, co-registered images from a single catheter and pullback combine the imaging depth of IVUS with the high-resolution detail of OCT, allowing physicians to assess complementary features of the same vessel segment.
· Image quality: The platform includes enhancements designed to improve image quality, supporting visualization of vessel structures and detailed assessment of lesions and stent deployment.
· Catheter deliverability: An updated catheter design is intended to improve deliverability through coronary anatomy and facilitate access to the areas physicians need to assess.
· Ease of use: The patient interface module, which connects the catheter to the system, is positioned outside the sterile field. This configuration and a streamlined catheter connection workflow are designed to simplify setup and use in the catheterization laboratory.
· Contrast mitigation: Access to IVUS imaging without a contrast flush allows physicians to use IVUS for selected imaging steps and OCT where additional high-resolution detail is needed, supporting a tailored approach to contrast use.
The first clinical cases were completed ahead of Conavi’s participation in Transcatheter Cardiovascular Therapeutics 2026. The Company also introduced OCTIV as the commercial name for its next-generation system. The name brings together references to OCT and IVUS and is inspired by the musical term “octave,” reflecting two complementary imaging modalities working in harmony. OCTIV is powered by Conavi’s Novasight technology.
Other related developments from around the markets include:
Philips, a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026. Philips brings together expertise in diagnostic and interventional cardiology, image-guided therapy and informatics to support cardiovascular care, from diagnosis through intervention and follow-up. As part of its presence at TCT, Philips will showcase innovations that support clinical confidence, streamline workflows and make meaningful information easier to access, while engaging with customers and clinical leaders on opportunities to better connect diagnostic and interventional care. Cardiovascular teams often work across separate imaging, hemodynamic, documentation and reporting systems. This can require repeated data entry and delay access to the complete clinical information needed for procedure reporting, coding and follow-up. In Philips’ Future Health Index 2025: Cardiology Snapshot, 79% of cardiac care professionals surveyed reported losing clinical time because patient data was incomplete or inaccessible. Almost half of this group reported losing more than 45 minutes per shift [1]. These findings underline the need to make clinical information easier to capture, access and reuse across the care pathway.
Boston Scientific generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $582 million or $0.40 per share (EPS), compared to $755 million or $0.51 per share a year ago, and achieved adjusted3 EPS of $0.73 for the period, compared to $0.75 a year ago. "This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation."
Terumo announced the global commercial launch of its K-Pack Embrace™ active safety needle. The new safety injection needle is packaged in a rigid cap and case container, designed to facilitate the downstream co-packing processes and protect the needle through the product life cycle until the point of use. Co-packing a pre-selected injection needle with a drug product and syringe can significantly reduce the risks to the patient, add convenience for the healthcare professional (HCP) and simultaneously maintain the value proposition of the product for the drug company. Automated co-packing processes require enhanced hard-shell protection of needles for easy handling during co-packing and to maintain needle sterility and performance over the product’s intended shelf life. The K-Pack Embrace™ active safety needle is designed specifically for automated co-packing processes with its compact hard-shell case. It is intended for subcutaneous (SC), intramuscular (IM) and intravenous (IV) applications and includes Terumo’s T-Sharp™ technology with integrated needle shield safety features. Available in either 1” (25mm) or 5/8” (16mm) lengths, the K-Pack Embrace™ 25-gauge needle is compatible with all ISO 80369-7 male connectors and its color-coded, tamper-evident label includes a 2D barcode (UDI carrier) that supports automated in-line visual inspection.
K-Pack Embrace™ reduces the risk of needle stick injuries with its integrated hinged needle shield, which can be activated with one hand and provides audible, visual and tactile confirmation of engagement.
Heartflow, Inc., the leader in AI technology for diagnosing and managing coronary artery disease (CAD), announced late-breaking one-year results from an independent randomized clinical trial proving the Heartflow FFRCT Analysis safely and significantly reduced unnecessary invasive heart procedures by 44% (p < 0.001). Presented as Late-Breaking Science at the European Society of Cardiology (ESC) Congress 2026, FUSION trial, funded by the Dutch National Health Care Institute, demonstrates that standard coronary computed tomography angiography (CCTA) alone drives overutilization of invasive catheterizations.1 By adding Heartflow FFRCT Analysis to standard CCTA scans, clinicians dramatically reduced diagnostic catheter lab procedures. The FUSION study has been published simultaneously in the Journal of the American College of Cardiology (JACC). CCTA is the primary first-line test recommended by both European (ESC) and U.S. (ACC/AHA) guidelines for evaluating patients with suspected CAD. However, visual assessment of CCTAs is limited to assessing anatomy and whether plaque is present; it cannot determine lesion-specific physiology or whether a blockage significantly restricts blood flow to the heart. This diagnostic uncertainty frequently leads physicians to refer patients for invasive coronary angiography (ICA), a hospital procedure where a catheter is threaded through an artery, normally in the groin or arm, to get into the heart to assess blocked or narrowed blood vessels.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Conavi Medical. by Conavi Medical. We own ZERO shares of Conavi Medical. Winning Media and its principals participated in a financing of the issuer and currently beneficially own seven hundred five thousand one hundred freely tradable shares. Winning Media and/or its principals may sell some or all of these shares in the open market at any time, which could negatively impact the issuer’s share price. Please click here for full disclaimer.
Contact:
Ty Hoffer
Winning Media
281.804.7972
Ty@winning.media
Related Stories
